Martin Schain, Imaging Director at Antaros Medical, presented at the 2nd GLP2 Based Therapeutics Summit this week. In his talk ‘How imaging can elucidate effects of incretin therapies – from muscle preservation to neuroprotection’ he discussed the value of imaging in clinical trials to further understand the effects of GLP1-based therapies and combinations.
Key talking points were:
• Underneath the lost kilos: what different imaging can bring with regards to body composition, muscle, and organ effects insights
• Neuroimaging with PET and MRI deepens our understanding of the link between metabolic dysfunction and neurodegenerative disease, and can clarify neuroprotective effects of GLP1 RA
• The future for incretin-based therapies is multi-fold and requires tools and biomarkers to elucidate novel combinations and expansion into new indications and disease areas
To learn more about incretins and drug development, weight loss in obesity and metabolic disease, you can also check out our webinars: The Incretin impact: A new era in metabolic disease and obesity development and Underneath the lost kilos: weight loss in metabolic disease